Division of Cardiovascular medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio; Centre de compétence en hypertension pulmonaire 27/76, Centre Hospitalier Universitaire Charles Nicolle, Rouen, France; INSERM EnVI U1096, Université de Rouen, France.
Centre de compétence en hypertension pulmonaire 27/76, Centre Hospitalier Universitaire Charles Nicolle, Rouen, France.
J Heart Lung Transplant. 2022 Dec;41(12):1761-1772. doi: 10.1016/j.healun.2022.09.005. Epub 2022 Sep 14.
Although ventriculoarterial coupling is associated with better survival in pulmonary arterial hypertension (PAH), existing PAH risk assessment method has not considered echocardiographic criteria of right ventricular to pulmonary artery coupling. We aimed to test the prognostic value of the echocardiographic tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/sPAP) ratio for noninvasive PAH risk assessment.
We retrospectively studied a cohort of 659 incident PAH patients from 4 independent French PH centers (training cohort: n = 306, validation cohort n = 353) who underwent follow-up TAPSE/sPAP measurement in addition to previously validated noninvasive risk stratification variables. The primary composite outcome was 3-year all-cause mortality or lung transplantation from re-evaluation.
Mean age was 55 ± 17 years-old with a majority of female (66%). The three main PAH causes were connective tissue disease (26%), idiopathic (24%) and porto-pulmonary (19%). The primary composite outcome occurred in 71 (23%) patients. Multivariable Cox regression analysis retained 3 noninvasive low-risk criteria as associated with the primary composite outcome: NYHA I-II (p = 0.001), NTproBNP <300 ng/L or BNP <50 ng/L (p = 0.004), and TAPSE/sPAP >0.33 mm/mmHg (p = 0.004). The more the low-risk criteria achieved at follow-up, the better the event-free survival both in the training and validation cohort (log-rank p < 0.001). In the training cohort, the c-index for these 3 criteria, for COMPERA 2.0 and for the noninvasive French Pulmonary Hypertension Network method were 0.75, 95%CI(0.70-0.82), 0.72 95%CI(0.66-0.75), 0.71 95%CI(0.62-0.73), respectively.
The 3 following dichotomized low-risk criteria: TAPSE/sPAP >0.33 mm/mmHg, NYHA I-II and NTproBNP <300 ng/L or BNP <50 ng/L allow to identify low-risk PAH patients at follow-up.
尽管心室动脉偶联与肺动脉高压(PAH)患者的生存率提高相关,但现有的 PAH 风险评估方法并未考虑右心室到肺动脉偶联的超声心动图标准。我们旨在检验超声心动图三尖瓣环平面收缩期位移/收缩期肺动脉压(TAPSE/sPAP)比值对无创性 PAH 风险评估的预后价值。
我们回顾性研究了来自法国 4 个独立 PH 中心的 659 例新发 PAH 患者(训练队列:n=306,验证队列 n=353),这些患者除了接受之前验证过的无创风险分层变量外,还进行了随访 TAPSE/sPAP 测量。主要复合终点是 3 年全因死亡率或肺移植。
平均年龄为 55±17 岁,大多数为女性(66%)。PAH 的三个主要病因是结缔组织疾病(26%)、特发性(24%)和门脉高压(19%)。主要复合终点发生在 71 例(23%)患者中。多变量 Cox 回归分析保留了 3 个与主要复合终点相关的无创低危标准:纽约心脏病协会(NYHA)心功能分级 I-II 级(p=0.001)、氨基末端脑钠肽前体(NTproBNP)<300ng/L 或 B 型利钠肽(BNP)<50ng/L(p=0.004),以及 TAPSE/sPAP>0.33mm/mmHg(p=0.004)。在训练和验证队列中,随着随访中低危标准的实现,无事件生存率越好(对数秩检验,p<0.001)。在训练队列中,这 3 个标准、COMPERA 2.0 和法国肺高血压网络无创方法的 C 指数分别为 0.75(95%CI:0.70-0.82)、0.72(95%CI:0.66-0.75)、0.71(95%CI:0.62-0.73)。
TAPSE/sPAP>0.33mm/mmHg、NYHA I-II 和 NTproBNP<300ng/L 或 BNP<50ng/L 这 3 个二分类低危标准可用于识别随访中的低危 PAH 患者。